[Health outcomes of deprescribing proton pump inhibitors: study protocol].

Revista espanola de salud publica Pub Date : 2025-02-26

Amaya Echeverría Gorriti, Andrea Rodríguez Esquiroz, Patricia García González, Lorea Sanz Álvarez, Marta Marín Marín, Javier Gorricho Mendívil, Julen Fernández González, Mª Concepción Celaya Lecea, Ana Campillo Arregui, Rebeca Irisarri Garde, Javier Garjón Parra

{"title":"[Health outcomes of deprescribing proton pump inhibitors: study protocol].","authors":"Amaya Echeverría Gorriti, Andrea Rodríguez Esquiroz, Patricia García González, Lorea Sanz Álvarez, Marta Marín Marín, Javier Gorricho Mendívil, Julen Fernández González, Mª Concepción Celaya Lecea, Ana Campillo Arregui, Rebeca Irisarri Garde, Javier Garjón Parra","doi":"","DOIUrl":null,"url":null,"abstract":"Objective: Proton pump inhibitors (PPI) are one of the groups of drugs with the highest prevalence of use. However, in many cases they are used for the treatment of unapproved indications. For this reason, in Navarra a strategy was implemented to deprescribe PPI in those cases in which their use was not indicated. Subsequently, a project was designed in order to analyze the health outcomes of that PPI deprescription strategy.Methods: A retrospective cohort study will be developed to evaluate health outcomes obtained after the implementation of the PPI deprescription strategy. The primary outcome will be the time until a serious adverse event, defined as one that causes hospital admission or death. We will analyze whether there are differences between patients who stopped PPI treatment and those who maintained it.Conclusions: It is expected to obtain information on the health outcomes of the proton pump inhibitor deprescription strategy and information about the convenience of continuing it.","PeriodicalId":94199,"journal":{"name":"Revista espanola de salud publica","volume":"99 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista espanola de salud publica","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Proton pump inhibitors (PPI) are one of the groups of drugs with the highest prevalence of use. However, in many cases they are used for the treatment of unapproved indications. For this reason, in Navarra a strategy was implemented to deprescribe PPI in those cases in which their use was not indicated. Subsequently, a project was designed in order to analyze the health outcomes of that PPI deprescription strategy.

Methods: A retrospective cohort study will be developed to evaluate health outcomes obtained after the implementation of the PPI deprescription strategy. The primary outcome will be the time until a serious adverse event, defined as one that causes hospital admission or death. We will analyze whether there are differences between patients who stopped PPI treatment and those who maintained it.

Conclusions: It is expected to obtain information on the health outcomes of the proton pump inhibitor deprescription strategy and information about the convenience of continuing it.

本刊更多论文

[处方质子泵抑制剂的健康结果：研究方案]。

目的：质子泵抑制剂（PPI）是目前使用率最高的一类药物。然而，在许多情况下，它们被用于治疗未经批准的适应症。出于这个原因，在纳瓦拉实施了一项策略，在那些不需要使用PPI的病例中取消PPI的处方。随后，设计了一个项目，以分析该生产者计划取消处方战略的健康结果。方法：将开展一项回顾性队列研究，以评估实施PPI去处方策略后获得的健康结果。主要结果将是发生严重不良事件的时间，定义为导致住院或死亡的事件。我们将分析停止PPI治疗和继续使用PPI治疗的患者之间是否存在差异。结论：本研究旨在获得质子泵抑制剂减处方策略的健康结果和继续减处方的便利性信息。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista espanola de salud publica

自引率

0.00%

发文量